A novel synthetic “switch” has been developed that could hold the key to revolutionary smart insulin therapy for diabetic patients.
List view / Grid view
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Researchers at UT Southwestern have invented a novel microscopy method that could open new avenues of advanced microscopy.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
Application note: Improving and simplifying the design of knock-in experiments using the TrueDesign Genome Editor
Genome editing technologies have given investigators the power to unlock a variety of new applications and experimental approaches. While gene knockouts have been achievable for several years, successful gene knock-ins have remained elusive due to the low efficiency of homology-directed repair (HDR).
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
Product hub: The world’s first BioPharma Lifecycle Management system – navigating your biopharma lifecycle
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
TALEN was shown to be almost five times more efficient than CRISPR-Cas9 at locating and editing genes in heterochromatin.